Literature DB >> 469561

3-Methylhistidine excretion as an index of myofibrillar protein catabolism in neuromuscular disease.

R O McKeran, D Halliday, P Purkiss, P Royston.   

Abstract

Myofibrillar protein catabolism has been calculated in a variety of neuromuscular diseases from the amount of 3-methylhistidine excreted in the urine. It was found to be significantly raised in Duchenne type muscular dystrophy, motor neurone disease, polymyositis, and thyrotoxic myopathy. In Becker type muscular dystrophy the level was slightly raised. It was normal in scapuloperoneal and limb girdle dystrophy, dystrophia myotonica, extrapyramidal disease, and multiple sclerosis. It was significantly decreased in hypothyroid myopathy.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 469561      PMCID： PMC490258          DOI： 10.1136/jnnp.42.6.536

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  27 in total

1.  The measurement of creatinine in plasma and urine.

Authors:  K D EDWARDS; H M WHYTE
Journal:  Aust J Exp Biol Med Sci       Date:  1958-08

2.  Chemical changes in skeletal muscle during development.

Authors:  J W DICKERSON; E M WIDDOWSON
Journal:  Biochem J       Date:  1960-02       Impact factor: 3.857

3.  The relationship of body composition to oxygen consumption and creatinine excretion in healthy and wasted men.

Authors:  R J RYAN; J D WILLIAMS; B M ANSELL; L M BERNSTEIN
Journal:  Metabolism       Date:  1957-07       Impact factor: 8.694

4.  Urinary creatinine excretion and lean body mass.

Authors:  G B Forbes; G J Bruining
Journal:  Am J Clin Nutr       Date:  1976-12       Impact factor: 7.045

5.  Fractional flux rates of Nt-methylhistidine in skin and gastrointestine: the contribution of these tissues to urinary excretion of Nt-methylhistidine in the rat.

Authors:  N Nishizawa; T Noguchi; S Hareyama; R Funabiki
Journal:  Br J Nutr       Date:  1977-07       Impact factor: 3.718

Review 6.  Actin and myosin and cell movement.

Authors:  T D Pollard; R R Weihing
Journal:  CRC Crit Rev Biochem       Date:  1974-01

7.  Increased myofibrillar protein catabolism in Duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine.

Authors:  R O McKeran; D Halliday; P Purkiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-10       Impact factor: 10.154

8.  Therapeutic trials in muscular dystrophy. 1. Gold in murine dystrophy.

Authors:  A Enomoto; W G Bradley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

9.  Musle protein breakdown rates in humans based on Ntau-methylhistidine (3-methylhistidine) content of mixed proteins in skeletal muscle and urinary output of Ntau-methylhistidine.

Authors:  C Bilmazes; R Uauy; L N Haverberg; H N Munro; V R Young
Journal:  Metabolism       Date:  1978-05       Impact factor: 8.694

10.  Comparison of human myofibrillar protein catabolic rate derived from 3-methylhistidine excretion with synthetic rate from muscle biopsies during L-[alpha-15N]lysine infusion.

Authors:  R O McKeran; D Halliday; P Purkiss
Journal:  Clin Sci Mol Med       Date:  1978-05
View more
  11 in total

Review 1.  Investigation of muscle disease.

Authors:  F L Mastaglia; N G Laing
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

Review 2.  Contractile proteins in muscle disease.

Authors:  P Cummins
Journal:  J Muscle Res Cell Motil       Date:  1983-02       Impact factor: 2.698

3.  Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.

Authors:  M Elia; A Carter; S Bacon; C G Winearls; R Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

4.  Proteases in normal and diseased human skeletal muscle: a preliminary histochemical survey.

Authors:  M G White; P J Stoward; K N Christie; J M Anderson
Journal:  Histochem J       Date:  1985-07

5.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

6.  Myofibrillar protein degradation in the chicken. 3-Methylhistidine release in vivo and in vitro in normal and genetically muscular-dystrophic chickens.

Authors:  F B Hillgartner; A S Williams; J A Flanders; D Morin; R J Hansen
Journal:  Biochem J       Date:  1981-05-15       Impact factor: 3.857

7.  Effect of experimental hyperthyroidism on skeletal-muscle proteolysis.

Authors:  W J Carter; W S van der Weijden Benjamin; F H Faas
Journal:  Biochem J       Date:  1981-03-15       Impact factor: 3.857

8.  Metabolomics Profiling of Patients With A-β+ Ketosis-Prone Diabetes During Diabetic Ketoacidosis.

Authors:  Farook Jahoor; Jean W Hsu; Paras B Mehta; Kelly R Keene; Ruchi Gaba; Surya Narayan Mulukutla; Eunice Caducoy; W Frank Peacock; Sanjeet G Patel; Rasmus Bennet; Ake Lernmark; Ashok Balasubramanyam
Journal:  Diabetes       Date:  2021-05-21       Impact factor: 9.337

9.  The Influence of Dietary Habits and Meat Consumption on Plasma 3-Methylhistidine-A Potential Marker for Muscle Protein Turnover.

Authors:  Bastian Kochlik; Christiana Gerbracht; Tilman Grune; Daniela Weber
Journal:  Mol Nutr Food Res       Date:  2018-04-19       Impact factor: 5.914

10.  Metabolomics Analysis of Skeletal Muscles from FKRP-Deficient Mice Indicates Improvement After Gene Replacement Therapy.

Authors:  Charles Harvey Vannoy; Victoria Leroy; Katarzyna Broniowska; Qi Long Lu
Journal:  Sci Rep       Date:  2019-07-11       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.